Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

haematological cancer

- PMLiVE

BMS’ Zeposia gains FDA approval in ulcerative colitis

Treatment was initially approved in 2020 for multiple sclerosis

- PMLiVE

BMS links up with Exscientia for $1.2bn AI drug discovery deal

Deal focuses on the use of AI to discover drug candidates across a number of therapeutic areas

- PMLiVE

BMS builds case for cardiovascular drug mavacamten with new analysis

BMS initially picked up mavacamten as part of its $13.1bn acquisition of MyoKardia last year

- PMLiVE

NICE recommends Keytruda for colorectal cancer patients with rare mutations

Approximately 450 patients in England will now become eligible for this treatment on the NHS

- PMLiVE

New trial data for Keytruda in triple-negative breast cancer

Keytruda plus chemotherapy showed significant and meaningful improvement

- PMLiVE

FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer

Approval is based on positive overall response rate (ORR) data from KEYNOTE-811 trial

- PMLiVE

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

Checkpoint inhibitor plus tyrosine kinase inhibitor approved for the first-line treatment of advanced renal cell carcinoma

- PMLiVE

Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients

Combination increases complete response rate to 24% compared to chemotherapy alone

- PMLiVE

BMS and bluebird bio gain FDA approval for multiple myeloma therapy

Abecma is a CAR T cell therapy approved for pre-treated myeloma patients

- PMLiVE

Keytruda plus chemotherapy gains US approval for advanced oesophageal cancer

First checkpoint inhibitor to win approval in the first-line setting for this cancer type

- PMLiVE

FDA accepts BMS’ investigational cardiovascular drug mavacamten for review

BMS gained the rights to mavacamten as part of its acquisition of MyoKardia

- PMLiVE

NICE rejects Keytruda for advanced bladder cancer in final guidance

Treatment had been authorised for use in this indication via the Cancer Drugs Fund in 2018

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links